Dexmedetomidine Sedation for Awake Fibreoptic Bronchoscopy

Feasibility and Safety of Dexmedetomidine Sedation for Patients presenting for Awake Fibreoptic Bronchoscopy

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000304336

Enrollment

100

Registered

2008-06-20

Start date

2008-12-15

Completion date

2009-03-02

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We aim to trial dexmedetomidine as a sedating agent for awake diagnostic fibreoptic bronchoscopy. It has a number of unique properties which we feel would be useful - sedating, reduces discomfort and stress during potentially uncomfortable procedures. We would be monitoring for any problems or adverse events during this trial.

Interventions

Dexmedetomidine sedation as an intravenous infusion to obtain sedation. Initial bolus of 0.5mcg/kg over 10 minutes followed by an infusion of 0.2-0.7mcg/kg/h, titrating to a Ramsay Sedation Score of 4 during the procedure. This infusion would be ceased once bronchoscopy is completed. The estimated time for the bronchoscopy would be about 15-20 minutes.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

18 years and above, Presenting for awake fibreoptic bronchoscopy, and Not pregnant at the start of the procedure/sedation

Exclusion criteria

Allergy to dexmedetomidine,2nd degree heart block and above,Hypovolaemia,Hypotensive at the start of the procedure/sedation

Outcome results